Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data

Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data — Live Feedhttps://www.live-feeds.com/feed/foghorn-lays-off-40-of-employees-as-lilly-cancer-collab-collapses-over-poor-dataContinuously updated, source-cited coverage. Foghorn Lays Off 40% of Staff as Eli Lilly Cancer Partnership Failshttps://www.live-feeds.com/feed/foghorn-lays-off-40-of-employees-as-lilly-cancer-collab-collapses-over-poor-datahttps://www.live-feeds.com/feed/foghorn-lays-off-40-of-employees-as-lilly-cancer-collab-collapses-over-poor-data#u98910Sun, 04 Oct 2026 13:35:36 +0000Foghorn Therapeutics is cutting 40% of its workforce, reducing staff to approximately 65 employees, after its cancer drug development collaboration with Eli Lilly collapsed. The partnership termination follows disappointing phase 1 dose-escalation data for FHD-909, also known as LY4050784, which failed to show sufficient efficacy to advance into an expansion phase. Additionally, the companies decided to scrap work on a related selective SMARCA2 degrader and chose not to extend their 2021 partnership. Foghorn stated that this restructuring and pipeline reprioritization will extend its cash runw